Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs
Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.
纳斯达克上市公司Tharimmune, Inc.（纳斯达克股票代码：THAR）（"Tharimmune"或"公司"），一家临床阶段生物技术公司，致力于在免疫学和炎症领域开拓治疗方法，今日宣布已签署证券购买协议，通过定向增发募集约202万美元的募资。
The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.
该协议包括发行961,446股普通股（或普通股等效证券）和购买权证，可购买最多额外480,723股普通股。每股（或普通股等效证券）定价为2.10美元，并附带一项认股权证。认股权证行权价为每股2.031美元，六个月后成为行权期，并在发行日后五年半到期。预计本交易将于2024年12月9日左右结束，须符合惯例的成交条件。
